ArticleJournal of neuro-oncology2019

EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.

Koos E Hovinga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.